GLP-1 R
12mg / 24mg / 50mg / 100mg
A retatrutide-class triple-receptor research compound used in metabolic pathway investigations.
Bundle & save
Strength
- Ships in 24 hours
- HPLC & endotoxin verified
- Encrypted checkout
Research details
Areas of research interest
Retatrutide is studied mainly for body-weight reduction and glycemic control. Its Phase 3 program also covers obesity-related knee osteoarthritis pain and obstructive sleep apnea. It is the first GIP, GLP-1, and glucagon triple agonist to reach late-stage trials. Retatrutide is investigational and is not approved by FDA for any use.
Overview
Retatrutide (LY3437943) is a synthetic peptide that acts as an agonist at three receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Adding glucagon-receptor activity to dual incretin agonism is the main difference from tirzepatide.
Research summary
Phase 2 obesity trial. In a 48-week trial of 338 adults with obesity or overweight, body-weight reduction followed a clear dose-response pattern, reaching a mean of 24.2% in the highest-dose arm [1]. Gastrointestinal events were the most common adverse effects; they were dose-related and mostly mild to moderate [1].
Phase 3 program. In July 2026, Eli Lilly reported positive topline results from TRIUMPH-2 (obesity with type 2 diabetes) and TRIUMPH-3 (severe obesity with cardiovascular disease), bringing the program to five positive Phase 3 studies [2]. Full results have not yet been published in peer-reviewed journals [2].
Regulatory status. Lilly plans to submit a Biologics License Application to FDA in the first quarter of 2027 [2].
References
- 1. Jastreboff AM, et al. N Engl J Med. 2023;389(6):514–526. PMID: 37366315
- 2. Eli Lilly and Company. Press release, July 23, 2026. TRIUMPH-2 (NCT05929079), TRIUMPH-3 (NCT05882045)
For laboratory research use only. Not for human or veterinary use. This product is not a drug, food, cosmetic, or dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.